High blood levels of the antibody immunoglobulin G, or IgG, at diagnosis are linked to a more severe disease course among people with primary…
News
CHOLESTASIS
NewsAI model may predict cholestasis-related cognitive impairment risk
An artificial intelligence (AI) model can accurately discriminate between cholestasis patients with and without moderate to severe disease-associated cognitive impairment based on 13 possible…
FATTY LIVER DISEASE
NewsAmerican Liver Foundation gears up for advocacy summit
Patients, caregivers, and supporters will head to Washington later this month to advocate for policies to improve life for people living with fatty liver…
BILIARY ATRESIA
NewsNew AI model helps make accurate diagnoses of biliary atresia
A new artificial intelligence (AI) model based on clinical data along with laboratory results and ultrasound images aids the early diagnosis of biliary atresia,…
The U.S. Food and Drug Administration (FDA) has granted fast track status to PBGENE-HBV, Precision Bioscience’s gene-editing therapy candidate for chronic hepatitis B…
Supporters are gearing up for World Liver Day on April 19 — marked by a global campaign to raise awareness about liver health and…
CHOLESTASIS
NewsFDA approves Livmarli oral tablets for PFIC, Alagille
The U.S. Food and Drug Administration (FDA) has approved an oral tablet formulation of Livmarli (maralixibat) to treat progressive familial intrahepatic cholestasis (PFIC)…
FATTY LIVER DISEASE
NewsGLP-1 agonists linked to lower risk of complications in MASLD, MASH
Use of glucagon-like peptide-1 (GLP-1) receptor agonists in people with metabolic dysfunction-associated steatotic liver disease (MASLD) or metabolic dysfunction-associated steatohepatitis (MASH) — forms of…
ALAGILLE SYNDROME
NewsCOVID-19 complicates vascular problems in woman with Alagille
A 34-year-old woman with Alagille syndrome and vascular problems — who had been implanted with a stent for her narrowed pulmonary arteries — experienced…
The first participant has been dosed in a Phase 3 clinical trial testing Atea Pharmaceuticals’ combination therapy bemnifosbuvir and ruzasvir in adults with chronic…
Recent Posts
- For girl in Asia, limited access to genetic testing delayed an Alagille diagnosis
- FDA gives bepirovirsen priority review for chronic hepatitis B
- Starting disease marker levels may shape Iqirvo response in PBC
- The possibility for liver function to improve brings me hope
- New mouse model could help guide PFIC3 treatment research